Kornimate/medical-research-clean huggingface dataset:
comprehensive oncology measures for peripheral t-cell lymphoma treatment registry

Conditions: Peripheral T-cell Lymphoma

Summary: prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral t-cell lymphoma (ptcl) are treated in academic and community practices.

the complete registry is a prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral t-cell lymphoma (ptcl) are treated in academic and community practices. the registry will enroll newly-diagnosed patients with ptcl treated with a variety of regimens. the complete registry is designed to better understand ptcl patient characteristics, treatments, and outcomes to help design and understand future clinical trials.

Eligibility criteria:
inclusion criteria: * patient is newly diagnosed with peripheral t-cell lymphoma (ptcl): * aggressive natural killer (nk)-cell leukemia * adult t-cell lymphoma/leukemia (human t-cell leukemia virus \[htlv\] 1+) * angioimmunoblastic t-cell lymphoma * anaplastic large cell lymphoma (alcl), primary systemic type (alk+, alk-) * ptcl, not otherwise specified (nos) * t/nk-cell lymphoma, nasal type * enteropathy-type intestinal lymphoma * hepatosplenic t-cell lymphoma * subcutaneous panniculitis t-cell lymphoma * transformed mycosis fungoides (at diagnosis of transformation) * t-cell prolymphocytic leukemia (t-pll) * cutaneous gamma/delta (γ/δ) t-cell lymphoma * cutaneous aggressive cd8+ t-cell lymphoma * hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm) * systemic epstein barr virus (ebv)+ t-cell lymphomas (t-cell lymphoproliferative disorders of childhood) * other t-cell lymphomas that are not listed in the exclusion criteria * patient gives written informed consent exclusion criteria: * patient has other t- or nk-cell malignancies including: * precursor t/nk neoplasms * t-cell large granular lymphocytic leukemia * mycosis fungoides, other than transformed mycosis fungoides * sézary syndrome * primary cutaneous cd30+ disorders: alcl and lymphomatoid papulosis

Keywords: non-hodgkins lymphoma non-hodgkin's lymphoma lymphoma
stereotactic body radiation therapy (sabr) for definitive treatment of locally advanced cervical cancer

Conditions: Locally Advanced Cervical Cancer

Summary: the purpose of this study is to determine whether sabr boost therapy is effective in women with locally advanced cervical cancer without increased risk of acute gastrointestinal (gi) or genitourinary (gu) toxicity.

patients enrolled in this study will receive 45 gray (gy) in 25 fractions of intensity modulated external beam radiation therapy + weekly cisplatinum . following the completion of intensity modulated radiation therapy (imrt), patients will receive 28 gy in 4 fractions using stereotactic body radiation therapy techniques.

Eligibility criteria:
inclusion criteria: 1 locally advanced stage cervical cancer 2. zubrod performance status 0-2 3. negative urine or serum pregnancy test for women of child-bearing potential 4. agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment 5. not a candidate for intracavitary brachytherapy exclusion criteria: 1. pregnancy 2. concurrent untreated cancer excluding non-melanoma skin cancer 3. previous pelvic radiation 4. active inflammatory bowel disease, collagen vascular disease - systemic lupus erythematosus (sle), scleroderma 5. age \<18 6. unable to consent for study 7. severely immunocompromised patients ( such as transplant , on immunosuppressive drugs)
remote-controlled capsule endoscopy: a feasibility study

Conditions: Gastric Ulcer; Gastric Polyp

Summary: the present study is a feasibility study to assess the safety and efficacy of wireless capsule endoscope and compare the data obtained with those obtained by using a conventional esophagogastroduodenoscopy. the product was developed and manufacture in china.(the navicam. akc-1.china)


Eligibility criteria:
inclusion criteria: * upper abdominal symptoms (≥1 year ) * surveillance gastroscopy for known gastric ulcer or polyps * history of gastric ulcer or polyps （≤1w）at nanfang hospital were enrolled. exclusion criteria: * dysphagia * suspected or documented digestive tract malformation ,obstruction, strictures or fistula * acute upper gi bleeding, acute enteritis, acute ischemia disease * history of abdominal operations * impaired renal function, congestive heart failure * patients with critical condition or mental illness * patients with, known allergy to polymer material or antifoam agent * patients with cardiac pacemakers or other implanted electromedical devices，magnetic resonance imaging ( mri) examination in 7 days * pregnancy
evaluation of triathlon - a new total knee prosthesis system - triathlon pa vs. triathlon pressfit

Conditions: Arthroplasty, Replacement, Knee

Summary: the objective is to investigate the clinical, radiographic, roentgen stereophotogrammetric behaviour and patient outcome when using the triathlon total knee prosthesis in a prospective randomized clinical trial.

the objective is to investigate the clinical, radiographic, roentgen stereophotogrammetric behaviour and patient outcome when using the triathlon total knee prosthesis in a prospective randomized clinical trial. the evaluation is carried out by a prospective randomised rsa-study with triathlon pa vs. triathlon pressfit

Eligibility criteria:
inclusion criteria: 1. patients suffering exclusively from oa, stage ii-v \[ahlbäck, 1968 391\] will be operated. 2. patients requiring knee prosthesis, suitable for the use of duracon and triathlon knee system 3. patients who understand the conditions of the study and are willing and able to comply with the post-operative scheduled clinical and radiographical evaluations and the prescribed rehabilitation. 4. patients who signed the ethics committee approved informed consent form prior to surgery. exclusion criteria: 1. previous major knee surgery 2. other significant disabling problems from the muscular-skeletal system than in the knees 3. obese patients where obesity is severe enough to affect subject's ability to perform activities of daily living (body mass index, kg/m2: bmi above 35). 4. patients with active or suspected infection. 5. patients with malignancy - active malignancy. 6. patients with severe osteoporosis, paget's disease, renal osteodystrophy. 7. patients immunologically suppressed, or receiving steroids in excess of physiologic dose requirements. 8. the patient has a neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device or the patient has a neurological deficit which interferes with the patient's ability to limit weight bearing or places an extreme load on the implant during the healing period. 9. female patients planning a pregnancy during the course of the study. 10. patients with systemic or metabolic disorders leading to progressive bone deterioration. 11. patients, who as judged by the surgeon, are mentally incompetent or are unlikely to be compliant with the prescribed post-operative routine and follow-up evaluation schedule. 12. patients with other severe concurrent joint involvements, which can affect their outcome. 13. patients with other concurrent illnesses, which are likely to affect their outcome such as sickle cell anaemia, systemic lupus erythematosus or renal disease requiring dialysis. 14. patients under the protection of law (e.g. guardianship).

Keywords: knee arthrosis implant
"clinical trial to determine the efficacy of vitamin d for acne therapy"

Conditions: Acne Vulgaris

Summary: the purpose of this study is to study the effects of topical vitamin d cream (calcipotriene, also known as dovonex) on acne. the information gained from this study may lead to new treatments for acne. in this study, calcipotriene will be compared with a placebo, a cream that looks like calcipotriene, but contains no active ingredients.

this study will be a randomized, double-blinded, parallel group comparison of calcipotriene vs. placebo cream. patients with acne will use calcipotriene or placebo cream 2x/day for 12 weeks and will be assessed at weeks 0, 2, 4, 8 and 12. each group will have 24 subjects as calculated by power analysis. three additional subjects for each group will be recruited for possible dropouts and total of 27 subjects will be recruited for each group. primary endpoint (lesion count) and secondary endpoint (iga- investigator's global assessment) will be determined. lesion counts will be assessed by one of the investigator physicians or nurse practitioner. adverse effects including irritation, dry skin, inflammation and worsening of the lesions will be noted at each visit. photographs will be taken to aid in assessing the clinical changes.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older, of either gender and any racial/ethnic group 2. subjects must have clinically evident mild to moderate acne vulgaris of the facial area, iga scale, grade 2-4 3. subjects must understand and sign the informed consent prior to participation 4. subjects must be in generally good health 5. subjects must be able and willing to comply with the requirements of the protocol exclusion criteria: 1. oral retinoid use within twelve months of entry into the study 2. systemic acne therapies (oral antibiotics) within 30 days of entry into the study 3. topical acne therapies (retinoids, antibiotics) within 14 days of entry into the study 4. non-compliant patients 5. pregnant or nursing women 6. subjects with a significant medical history or concurrent condition that the investigator(s) feel is not safe for study participation 7. subjects with hypercalcemia (hyperparathyroidism, kidney disease) 8. subjects who cannot avoid excessive exposure to either natural or artificial sunlight.
improving aspirin prescription rates in outpatient clinic

Conditions: Low Birth Weight; Small for Gestational Age (SGA); Preeclampsia (PE); Prevention &Amp; Control

Summary: ρrееςlаmpѕia is a syndrome characterised by the new onset of hуреrtеnѕion plus proteinuria, end-organ dysfunction, or both after 20 weeks of gestation. it complicates 3-5% of pregnancies. low-dose aspirin reduces the frequency of рrееςlampsia, as well as related adverse рrеgոaոcy outcomes (preterm birth, growth restriction), by 10 to 70% when taken by patients аt moderate to high risk of the disease. it has an excellent maternal/fetal safety profile. thus, it is a reasonable preventive strategy for these patients. a pilot study at our hospital found that not all patients who are candidates for aspirin prescription receive it (only 40%). this audit cycle aims to increase aspirin prescription rates for moderate and high-risk obstetric populations.


Eligibility criteria:
inclusion criteria: women at high risk are those with any of the following: 1. hypertensive disease during a previous pregnancy 2. chronic kidney disease 3. autoimmune disease such as systemic lupus erythematosus or antiphospholipid syndrome 4. type 1 or type 2 diabetes 5. chronic hypertension. women with more than one moderate risk factor, such as are: 1. nulliparity 2. age 40 years or older 3. pregnancy interval of more than 10 years 4. body mass index (bmi) of 35 kg/m2 or more at first visit 5. family history of pre-eclampsia 6. multi-fetal pregnancy. exclusion criteria: * none. all eligible candidates will be included.

Keywords: aspirin preeclampsia obstetric risk population
consultation at 8 days to reduce hospitalisations in heart failure patient

Conditions: Acute Heart Failure

Summary: evaluate the benefit of systematic appointment with a cardiologist a week after hospitalisation for acute heart failure. randomised, endpoint: number of day alive out of hospital during 6 months

background: the risk for rehospitalisation is very high after hospitalisation for acute heart failure. aim: evaluate the benefit of a consultation with a cardiologist, including echocardiography and education of the patient, between 7 and 15 days after discharge, in high risk patients, identified with bnp or incomplete therapy. parallel randomised study. the main endpoint is the number of day alive out of hospital during the 6 months post discharge; statistics intention to treat comparison of the number of days alive out of hospital in the group with consultation compared with the group without consultation. recruitment 3 years and 4 months, follow-up 6 months. patients included have been hospitalised in hospital bichat 75018 paris, france. financing is by the ministry of health (phrqhos)

Eligibility criteria:
criteria of inclusion : * patient with decompensated heart failure hospitalized in the hospital bichat, * for whom is planned a return at home, * valid (being able to return for a consultation to the hospital) * having nt-probnp of exit ≥ 3500 ng /l and/or a non optimized treatment of exit - according to the doctor who has it the responsibility, * having signed the consent form by participation in the study. criteria of not inclusion : * age \< 18 years, * not membership in a national insurance scheme or in the universal health * coverage (cmu)(free universal health care)(a patient benefiting from the medical aid of the state (ame) cannot be included) * participation to another protocol of research, * not being reachable by telephone in 6 months.

Keywords: acute heart failure; rehospitalisation; education; follow-up
prostate cancer in renal transplants recipients

Conditions: Prostate Cancer; Renal Transplantation; Kidney Transplant Recipients

Summary: kidney transplantation is considered the standard of care for patients with end-stage kidney disease under chronic dialysis treatment. today, modern surgical techniques have dramatically improved the quality of life and the overall survival of renal transplant recipients (rtrs) . besides, the use of novel immunosuppressors have increased the 1-year graft survival rate and decreased acute rejection rate . unfortunately, several transplantation-related diseases including cancer, cardiovascular disease and infection may affect the survival of renal transplant recipients. it has been estimated that rtrs are 2- to 5- fold more likely to develop cancer compared to the general population. therefore, the development of cancer has become a major concern as it is currently one of the main causes of death in rtrs. the increasing incidence of post-transplant malignancies is generally attributed to immunosuppression which leads to impaired immunosurveillance of cancer cells and virals infections capable of cancer development. additionally, it has been observed a direct and specific pro-oncogenic effect on rtrs of immunosuppressive drugs and other immunosuppression-independent factors such as the increased age of rtrs, the male gender and the pre-transplant dialysis duration . prostate cancer is the second most diagnosed cancer in men and the most common non-skin solid neoplasm in rtrs. generally, the vast majority of post kidney transplantation prostate cancers are localised; however, due to the lack of randomized studies, no specific guidelines for the management of localized prostate cancer are available and, consequently, rtr patients are being treated with surgery or radiotherapy according to national or local guidelines. the concomitant use of immunosuppressors and the presence of the kidney graft in the pelvic cavity make the treatment of localised prostate cancer post kidney transplantation more challenging, highlighting the need for these patients to be addressed to urological oncology centres with surgeons familiar with oncological and transplant surgery. prostate cancer is the second most diagnosed cancer in men and the most common non-skin solid neoplasm in rtrs, however, little studies describe the real incidence of prostate cancer in rtrs. the aim of this study is to retrospectively review a 25-year experience at the florence transplant center in order to evaluate the incidence of prostate cancer and its possible clinical/pathological factors able to influence the survival.


Eligibility criteria:
inclusion criteria: * patient undergoing kidney transplantation in the period from july 1991 to september 2016 * development of prostate cancer confirmed histologically * written informed consent exclusion criteria: • lack of clinical and prognostic data on selected patients
phase 1 study to evaluate the pharmacokinetics and safety following sc administration of dwj108j in patients with prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to evaluate the pharmacokinetic characteristics and safety of dwj108j (leuprolide acetate) and leuplin dps inj administered subcutaneously in patients with prostate cancer


Eligibility criteria:
inclusion criteria: 1. males ≥19 and ≤80 years of age at screening. 2. subject with histologically proven adenocarcinoma of the prostate requiring androgen deprivation therapy 3. an ecog performance status grade of 0 to 2, 4. 19kg/m2≤ body mass index (bmi) ≤30kg/m2 at screening. exclusion criteria: 1. confirmed hormone refractory prostate cancer(hrpc) 2. has had history of bilateral orchiectomy, suprarenalectomy or hypophysectomy. 3. diagnosed pituitary adenoma 4. has a history of depression 5. has a risk of spinal cor d compression due to metastatic spinal cord injury. 6. has a severe urethratresia. 7. confirmed uncontrolled congestive heart failure (chf) within 6 months of screening. 8. has a history of mi or any procedure with regard to coronary artery disease within 6 months of screening. (e.g., balloon angioplasty, coronary artery bypass graft) 9. has any severe concomitant disease that would interfere with the conduct of the study except for prostate cancer 10. has allergy history of leuprolide acetate, similar gnrh drugs or other medications (e.g., aspirin, antibiotics) and/or has any allergic disease requiring treatment. 11. has received an investigational drug within 9 0days of screening. 12. drug releasing is expected after administration of study drug, if subject received gnrh agonist for treatment of prostate cancer. 13. has other chemotherapy planned within 14weeks from administration of study drug, except for androgen deprivation therapy. 14. has no willing of using method of contraception throughout the study period. 15. systolic blood pressure \< 90mmhg and/or ≥160mmhg or diastolic blood pressure \< 60mmhg and/or ≥100mmhg at screening 16. qtcf \>450msec at screening ecg. 17. hba1c level is high the upper limit of normal of reference range. 18. serum ast, alt or creatinine \> 1.5times the upper limit of normal at screening. 19. positive results of tests for hepatitis b, hepatitis c, hiv or syphilis. 20. has any condition that, in the opinion of the investigator, would make participation not be in the best interest of the subject.
a real world, observational registry of chronic wounds and ulcers

Conditions: Diabetic Foot; Varicose Ulcer; Pressure Ulcer; Surgical Wound Dehiscence; Vasculitis; Skin Ulcer; Leg Ulcer; Wounds and Injuries; Pyoderma; Peripheral Arterial Disease; Diabetic Neuropathies; Lymphedema; Venous Insufficiency; Diabetes Complications; Amputation Stump

Summary: more than 100 hospital based outpatient wound centers in the usa and puerto rico agree to transmit structured data on all patients followed with chronic wounds and ulcers (e.g. diabetic foot ulcers, venous ulcers, pressure ulcers, arterial ulcers, surgical wounds, and traumatic wounds). data are collected at point of care including adherence to wound care quality measures developed by the uswr as a qualified clinical data registry (qcdr).

this is a longitudinal, observational study of chronic wounds and ulcers treated at participating hospital based, outpatient wound centers. data collection began in 2005. structured data are collected at the point of care in the patient electronic health record and data from all patients at more than 100 wound centers in the usa and puerto rico are transmitted to the u.s. wound registry which is recognized by cms as a qualified clinical data registry (qcdr). participation in the uswr can satisfy the registry participation option for stage 2 of meaningful use. the dataset includes all wound and ulcer types such as diabetic foot ulcers, venous stasis ulcers, pressure ulcers, arterial ulcers, surgical wounds, traumatic wounds, vasculitic ulcers, arterial ulcers, sickle cell ulcers, inflammatory ulcers (e.g. pyoderma gangrenosum), and ulcers related to skin disorders such as scleroderma. interventions provided include advanced dressings, compression bandaging, off-loading, cellular and/or tissue based therapies, hyperbaric oxygen therapy, negative pressure wound therapy, debridement, and antibiotics. ulcers are risk stratified for outcomes reporting using the wound healing index.outcomes measured include healing or wound closure, surgical closure, death, and major and minor amputation. data on wound care specific quality measures developed by the qcdr are also available.

Eligibility criteria:
inclusion criteria: all wounds in all patients at participating centers - exclusion criteria: none -

Keywords: qualified clinical data registry quality measures meaningful use stage 2 electronic health records clinical data research network real world data
mindfulness for emerging adults experiencing anxious and/or depressive symptoms

Conditions: Depressive Symptoms; Anxious Symptoms

Summary: emerging adults (ea; 18 to 29 years old) in canada are among the age group with highest risk of developing mental health issues. despite this, they experience especially long wait-times for mental health services. to date, there has been minimal research into developmentally appropriate treatment options for the ea population. mindfulness-based interventions (mbis) are emerging as a potential treatment to address this need. mbis are group-based psychological treatments for coping with distress, with the goal of improving mental health. unfortunately, these 'traditional' mbis are very demanding in terms of time and homework and are therefore not sufficiently feasible for the demanding schedules of ea university students. instead, recent studies suggest a role for briefer mbis in addressing mental health symptom burden, well-being and reducing acute stress symptoms. the brevity of these interventions make them theoretically better suited for ea university populations. high quality research, including controlled clinical trials are needed to demonstrate whether mbis can provide efficacious treatment to improve the lives of ea university students. the current study will test the efficacy of a five-week mbi baseline within-subject controlled trial.


Eligibility criteria:
inclusion criteria: * consenting emerging adults * ability to communicate, in written and spoken english exclusion criteria: * minimal depressive and anxious symptoms (score below 10 and 8 on the phq-9/gad-7 * current substance abuse or dependence, psychosis or mania * current self-injurious behavior of past suicide attempt * previously completed \>4 weeks of an mbi, or general cognitive behavioral therapy, in the past 3 years

Keywords: mindfulness well-being emotion regulation perceived stress self-compassion